NiXEN announces the disposal of its shareholding in Ceva Santé Animale as a new round of funding takes shape

NiXEN announces its withdrawal from the capital of Ceva Santé Animale, as the group builds its fourth LBO around the management team, holder of a majority interest, and a number of minority investors, including Temasek and CDH Investments, to consolidate the group’s international ambitions, notably in Asia.

Ceva Santé Animale generated 2013 turnover of nearly €700 M, up from €350 M in 2007, and has continuously strengthened its position among the world’s top 10 veterinary groups, posting unbroken growth of business and profitability.

Based on historic relations with Ceva going back to 1999, NiXEN has actively accompanied the company’s international development, combining organic growth with acquisitions, notably in the international arena.

“We are proud to have contributed to the emergence of a high-performance, midsize French company, and we are delighted to have worked with a deeply committed, high-quality team that has proved its capacity to develop, showing strong discipline, prompt to react, and that has pursued a judicious policy focusing on strategic, high added-value products over the last few years”, said Philippe Taranto, Member of the NiXEN Management Committee.

 

“It has been a great pleasure to have NiXEN as a partner for the last seven years and I thank the fund for its commitment to Ceva and for the constructive and demanding dialogue that we have had throughout this period, notably at stages that have been pivotal in our development”, said Marc Prikazsky CEO of Ceva Santé Animale

 

Contributors:

NiXEN: Jean-Paul Bernardini, Philippe Taranto, Vincent Houlot